Daiichi Sankyo, the manufacturer of olmesartan products (including Benicar, Benicar HCT, Azor and Tribenzor) has agreed to a $300 million settlement fund to pay victims who suffered from sprue-like enteropathy and other severe gastro-intestinal symptoms.  Eligible claimants must act quickly to be eligible to receive compensation from this settlement fund.

Benicar Attorneys

Benicar, Tribenzor and Azor are prescription high blood pressure drugs. They may have serious gastrointestinal side effects which may resemble Celiac disease but usually are later diagnosed as sprue-like enteropathy or villous atrophy. Both are serious problems that can lead to malnutrition, intestinal damage and chronic diarrhea, and severe weight loss that sometimes requires hospitalization.

Benicar, Azor and Tribenzor Lawsuits

Benicar, Azor & Tribenzor Side Effects

There were numerous irregularities in the clinical trials that should have led the manufacturers to be aware of the incidence of gastrointestinal complaints. These warning signs were ignored, and instead, these drugs were aggressively marketed, leading to over 11 million prescriptions each year. The FDA sent a warning letter in 2006 saying that advertising of Benicar was misleading. In July 2013, the FDA required the addition of warnings regarding the risk of sprue-like enteropathy and villous atrophy to the drug labels of Benicar, Benicar HCT, Tribenzor, and Azor.

Do You Have a Benicar Case?

If you took any of these drugs and were diagnosed with sprue-like enteropathy and villous atrophy, or if you suffered diarrhea or severe weight-loss requiring hospitalization, you may have a claim for damages. Contact us today to find out.